The effect of atorvastatin and fluvastatin on antioxidative enzymatic activity was studied in CHD risk patients. The study comprised 35 patients (20 men and 15 women) aged 35-47 years, who were allotted into two groups: I--18 patients were administered fluvastatin (Lescol) in a dose of 40 mg once daily at bed time for 6 weeks and II--17 patients were administered atorvastatin (Sortis) in a dose of 10 mg once daily at bed time for 6 weeks. The control group consisted of 12 clinically healthy subjects, aged 34-42 years.
View Article and Find Full Text PDF